-
Something wrong with this record ?
Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors
O. Fiala, O. Sorejs, J. Sustr, R. Kucera, O. Topolcan, J. Finek,
Language English Country Greece
Document type Journal Article, Review
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
- MeSH
- Programmed Cell Death 1 Receptor antagonists & inhibitors MeSH
- Immunotherapy methods MeSH
- Humans MeSH
- Neoplasms drug therapy MeSH
- Drug-Related Side Effects and Adverse Reactions drug therapy MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Immunotherapy based on immune checkpoint inhibitors (ICIs) represents a novel anticancer treatment strategy. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA4), programmed cell death-1 receptor (PD1) and programmed cell death-1 ligand (PD-L1) have shown efficacy and safety in the treatment of various malignancies. Some of them have recently found their place in a routine clinical practice, while others are at different phases of clinical trials. Treatment with ICIs may be accompanied by undesirable impairment of immunotolerance to non-tumoural tissues, leading to a specific side-effect also called immune-related adverse events (irAE). There is an increasing body of evidence that the development of irAEs is associated with a beneficial effect of immunotherapy, thus it has become a hot topic in the field of clinical oncology. This review is focused on data from recently published studies evaluating the association between irAEs and outcome of patients with cancer treated with ICIs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023122
- 003
- CZ-PrNML
- 005
- 20201214125324.0
- 007
- ta
- 008
- 201125s2020 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/anticanres.14063 $2 doi
- 035 __
- $a (PubMed)32132018
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Medical School and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic fiala.o@centrum.cz. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- 245 10
- $a Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors / $c O. Fiala, O. Sorejs, J. Sustr, R. Kucera, O. Topolcan, J. Finek,
- 520 9_
- $a Immunotherapy based on immune checkpoint inhibitors (ICIs) represents a novel anticancer treatment strategy. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA4), programmed cell death-1 receptor (PD1) and programmed cell death-1 ligand (PD-L1) have shown efficacy and safety in the treatment of various malignancies. Some of them have recently found their place in a routine clinical practice, while others are at different phases of clinical trials. Treatment with ICIs may be accompanied by undesirable impairment of immunotolerance to non-tumoural tissues, leading to a specific side-effect also called immune-related adverse events (irAE). There is an increasing body of evidence that the development of irAEs is associated with a beneficial effect of immunotherapy, thus it has become a hot topic in the field of clinical oncology. This review is focused on data from recently published studies evaluating the association between irAEs and outcome of patients with cancer treated with ICIs.
- 650 _2
- $a nežádoucí účinky léčiv $x farmakoterapie $7 D064420
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a nádory $x farmakoterapie $7 D009369
- 650 _2
- $a antigeny CD279 $x antagonisté a inhibitory $7 D061026
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Sorejs, Ondrej $u Department of Oncology and Radiotherapeutics, Medical School and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Sustr, Jan $u Department of Oncology and Radiotherapeutics, Medical School and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Kucera, Radek $u Department of Immunochemistry Diagnostics, Medical School and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Topolcan, Ondrej $u Department of Immunochemistry Diagnostics, Medical School and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Finek, Jindrich $u Department of Oncology and Radiotherapeutics, Medical School and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 40, č. 3 (2020), s. 1219-1227
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32132018 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125324 $b ABA008
- 999 __
- $a ok $b bmc $g 1595441 $s 1113798
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 40 $c 3 $d 1219-1227 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20201125
